Preclinical and clinical data on the targeting of this pathway in KRAS mutant tumors indicate that combination treatment of immunotherapies with allele-specific RAS inhibitors might enhance the anti-tumor efficacy of immunotherapy in RAS-mutant tumors. This evidence concerns the gene KRAS and neoplasm.